证券代码：300558 证券简称：贝达药业 公告编号：2024-059 贝达药业股份有限公司 关于公司及控股子公司通过美国 FDA 现场核查的公告 公司名称：Xcovery Holdings, Inc 地址：美国佛罗里达州，迈阿密市，一大街东南 168 号 11 楼 检查事由：美国 FDA 对恩沙替尼 NDA（New Drug Application，新药申请）的 批准前检查 检查范围：恩沙替尼临床Ⅰ、Ⅱ、Ⅲ期研究的 BIMO FDA FEI：3030490112 检查时间：2024 年 5 月 7 日至 2024 年 5 月 14 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）及控股子公司 Xcovery Holdings, Inc（以下简称"Xcovery"）分别于 2024 年 5、6 月接受了美国食 品药品监督管理局（以下简称"美国 FDA"）的临床 BIMO（Bioresearch Monitoring，生物研究监测）相关 PAI（Pre-Approval Inspection，批准前检查） 现场核查、原 ...

公 司 研 究 [Table_Reportdate] 2024年08月07日 [Table_invest] 买入（维持） 报告原因：业绩点评 [证券分析师 Table_Authors] 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 wkx@longone.com.cn 联系人 付婷 futing@longone.com.cn | --- | --- | |-------------------------|-------------| | 数据日期 Table_cominfo] | 2024/08/06 | | 收盘价 | 36.22 | | 总股本(万股) | 41,849 | | 流通A股/B股(万股) | 41,718/0 | | 资产负债率(%) | 39.14% | | 市净率(倍) | 2.72 | | 净资产收益率(加权) | 4.16 | | 12个月内最高/最低价 | 63.09/30.43 | [Table_QuotePic] -44% -30% -16% -2% 12% 26% 40% 54% 23-08 2 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company reported a revenue of 1.501 billion yuan for the first half of 2024, representing a year-on-year growth of 14.22%. The net profit attributable to shareholders was 224 million yuan, up 51.00% year-on-year, while the net profit excluding non-recurring items reached 217 million yuan, marking a significant increase of 144.98% year-on-year [1] - The company has maintained a rapid growth in profits and improved operational efficiency, with the ratio of period expenses to operating income decreasing from 77.14% to 67.25%, a decline of 9.89 percentage points [1] - The market performance of Beimeina and Saimeina has shown significant growth, with Beimeina's clinical application potential being continuously explored and its market accessibility greatly improved after being included in medical insurance [1][2] - The company has a robust pipeline with over 40 projects under development, including the self-developed CDK4/6 inhibitor BPI-16350, which has received NDA acceptance from NMPA [2][4] Summary by Sections Financial Performance - In the first half of 2024, the company achieved a revenue of 1.501 billion yuan, with a year-on-year growth of 14.22%. The net profit attributable to shareholders was 224 million yuan, reflecting a 51.00% increase year-on-year. The net profit excluding non-recurring items was 217 million yuan, up 144.98% year-on-year [1] - The operating cash flow for the first half of 2024 was 522 million yuan, a year-on-year increase of 44.77% [1] Product Development - The company is focusing on the commercialization of its products, with Beimeina and Saimeina showing strong market growth. Beimeina's postoperative adjuvant therapy is progressing well in clinical trials, and its market space is expected to expand further [1][2] - The self-developed CDK4/6 inhibitor BPI-16350 has received NDA acceptance, and the company is actively pursuing multiple clinical trials for various indications [2][4] Future Outlook - The company is expected to achieve net profits of 420 million yuan, 547 million yuan, and 665 million yuan for the years 2024, 2025, and 2026, respectively, with corresponding EPS of 1.00 yuan, 1.31 yuan, and 1.59 yuan [5] - The current stock price corresponds to a P/E ratio of 36, 28, and 23 for the years 2024, 2025, and 2026, indicating a favorable valuation [5]

证券研究报告 非金融公司|公司点评|贝达药业（300558） 收入稳健增长，利润表现亮眼 请务必阅读报告末页的重要声明 glzqdatemark1 2024年08月06日 证券研究报告 |报告要点 贝达药业发布 2024 年半年报，上半年实现收入 15.01 亿元（同比+14.22%），实现归母净利润 2.24 亿元（同比+51.00%），实现扣非归母净利 2.17 亿元（同比+144.98%）。业绩符合预期。 |分析师及联系人 夏禹 郑薇 SAC：S0590518070004 SAC：S0590521070002 请务必阅读报告末页的重要声明 1 / 5 非金融公司|公司点评 glzqdatemark2 2024年08月06日 贝达药业(300558) 收入稳健增长，利润表现亮眼 | --- | --- | |------------|-------------------| | 行 业： | 医药生物/化学制药 | | 投资评级： | 增持（维持） | | 当前价格： | 34.44 元 | 基本数据 总股本/流通股本(百万股) 418.49/417.16 流通 A 股市值(百万元) 14,366.85 ...

Investment Rating - The investment rating for the company is maintained at "Buy - A" with a target price of 51.34 CNY per share [2][3]. Core Insights - The company reported a revenue of 1.501 billion CNY for the first half of 2024, representing a year-on-year growth of 14.22%. The net profit attributable to shareholders was 224 million CNY, up 51.00% year-on-year, and the net profit excluding non-recurring items was 217 million CNY, reflecting a significant increase of 144.98% [1]. - The company is expected to benefit from the upcoming negotiations for the inclusion of Beifu in the National Medical Insurance catalog for first-line treatment of NSCLC, which could lead to substantial sales growth in 2025 [1]. - The company is actively advancing multiple products, including Ensartinib and CDK4/6 inhibitors, with significant clinical research progress noted [1]. Financial Performance - Revenue growth is projected at 24.78%, 24.90%, and 23.04% for 2024, 2025, and 2026 respectively, with net profit growth expected at 23.46%, 25.59%, and 22.23% for the same periods [2]. - The earnings per share (EPS) are forecasted to be 1.03 CNY, 1.29 CNY, and 1.58 CNY for 2024, 2025, and 2026 respectively, with corresponding price-to-earnings (PE) ratios of 33.5, 26.7, and 21.9 [2][7]. Product Pipeline and Clinical Research - The company has several products in various stages of development, including Ensartinib for ALK-positive NSCLC and CDK4/6 inhibitors for HR+/HER2- breast cancer, both of which have received regulatory acceptance [1]. - Ongoing clinical trials include Ensartinib for postoperative adjuvant therapy and Beifu for postoperative adjuvant therapy, with positive data reported for the EGFR/cMET dual antibody MCLA-129 [1].

Investment Rating - The report maintains a "Hold" rating for the company [1] Core Views - The company reported a strong performance in the first half of 2024, with revenue of 1.5 billion yuan, representing a 14.2% increase year-on-year, and a net profit of 220 million yuan, up 51% [2] - The significant profit growth is attributed to improved management of operating expenses and a focus on cost reduction and efficiency [2] - The company is advancing its innovative drug pipeline, with potential FDA approval for Ensatinib expected by the end of the year and ongoing applications for other products [2] - The company has a robust clinical trial pipeline, with several promising candidates progressing through the approval process [2] Summary by Sections Financial Performance - In the first half of 2024, the company achieved a net profit of 220 million yuan, a 145% increase in net profit after deducting non-recurring items [2] - The proportion of operating expenses to revenue decreased from 77.14% to 67.25%, a reduction of 9.89 percentage points [2] - The net cash flow from operating activities reached 521.69 million yuan, a year-on-year increase of 44.77% [2] Product Development - Ensatinib is expected to receive FDA approval by the end of 2024, and the company is progressing with the application for recombinant human serum albumin [2] - The company has received IND approvals for several new drug candidates, including EYP-1901 and pan-EGFR inhibitors [2] Earnings Forecast - The forecast for net profit for 2024-2026 is 450 million yuan, 580 million yuan, and 740 million yuan, respectively, with corresponding PE ratios of 32, 25, and 20 [3] - The core product, Alectinib, is expected to maintain stable performance, while new products like Ensatinib are anticipated to contribute to revenue growth [3] Market Position - The company has a total market capitalization of 14.41 billion yuan and a total asset value of 9.14 billion yuan [6] - The stock price has fluctuated between 30.78 yuan and 61.65 yuan over the past 52 weeks [6]

业绩简评 2024 年 8 月 5 日，公司公告，2024 年上半年营收 15.01 亿元，同比 增长 14.22%，归母/扣非净利润 2.24/2.17 亿元，同比增长 51.00%/ 144.98%。2024 年二季度营收 7.65 亿，同比下降 2.21%，归母/扣非 净利润 1.26/1.27 亿元，同比增长 29.82%/81.06%。业绩符合预期。 点评 深耕肺癌，凯美纳稳健，贝美纳接力，国内放量与美国获批值得期待。 （1）业绩：销售稳健，费用下降，利润高增长。公司已有五款药品 在售：凯美纳（埃克替尼）作为公司基石产品销量保持稳定，贝美纳 （恩沙替尼）和贝安汀（贝伐珠单抗）营收贡献增长明显，赛美纳（贝 福替尼）伏美纳（伏罗尼布）纳入医保后加快放量。公司上半年研发 费用 2.56 亿，同比下降 23%。（2）凯美纳，是国内首个原研小分子 肺癌靶向药，其一线、二线及术后辅助适应症全线纳入《国家医保目 录》后，产品生命周期进一步延长。作为三代 EGFR（表皮生长因子受 体）肺癌靶向药的赛美纳，其放量也值得关注。（3）贝美纳，是第 一个用于 ALK（间变性淋巴瘤激酶）阳性晚期非小细胞肺癌的国产 1 类新药 ...

Financial Performance - Revenue for the first half of 2024 reached RMB 2.5 billion, representing a 15% year-over-year increase[1] - Net profit for the first half of 2024 was RMB 500 million, up 20% compared to the same period last year[1] - Revenue for the reporting period reached 1.50 billion yuan, a 14.22% increase year-over-year[12] - Net profit attributable to shareholders of the listed company was 223.95 million yuan, up 51.00% compared to the same period last year[12] - Net cash flow from operating activities increased by 44.77% to 521.69 million yuan[12] - Basic earnings per share rose by 50.00% to 0.54 yuan per share[12] - The company expects full-year 2024 revenue to grow by 12-15% year-over-year, with net profit margin projected to be around 20%[1] - Revenue for the reporting period reached 1,500.77 million yuan, a year-on-year increase of 14.22%[32] - Net profit attributable to shareholders of the listed company was 223.95 million yuan, a year-on-year increase of 51.00%[32] - Revenue for the first half of 2024 reached 1,500.77 million yuan, a year-on-year increase of 14.22%[40] - Operating expenses as a percentage of revenue decreased from 77.14% to 67.25%, a reduction of 9.89 percentage points[40] - Net cash flow from operating activities was 521.69 million yuan, a year-on-year increase of 44.77%[40] - The net profit cash content reached 232.95%, and the sales cash realization rate was 109.28%[40] - Revenue for the reporting period increased by 14.22% to 1,500,765,619.93 yuan compared to the same period last year[57] - R&D investment decreased by 28.58% to 381,853,328.77 yuan compared to the same period last year[57] - Net cash flow from operating activities increased by 44.77% to 521,692,329.59 yuan due to increased cash inflows from product sales[57] - Net cash flow from financing activities decreased by 136.83% to -167,076,906.49 yuan due to reduced bank borrowings[57] - The gross profit margin for drug sales decreased by 0.95% to 84.35% compared to the same period last year[58] - Total revenue for the first half of 2024 reached 1,500,765,619.93 yuan, a 14.2% increase compared to 1,313,877,968.81 yuan in the same period of 2023[177] - Net profit attributable to the parent company increased to 2,446,026,001.91 yuan from 2,293,220,793.27 yuan, a 6.7% growth[174] - Total revenue for the first half of 2024 reached 1,496,617,316.45 RMB, compared to 1,310,705,635.48 RMB in the same period of 2023[180] - Net profit attributable to the parent company's shareholders increased to 223,947,809.09 RMB in H1 2024, up from 148,306,337.19 RMB in H1 2023[178] - Basic earnings per share (EPS) rose to 0.54 RMB in H1 2024, compared to 0.36 RMB in H1 2023[179] - Operating profit surged to 253,891,097.59 RMB in H1 2024, a significant increase from 86,438,503.18 RMB in H1 2023[178] - Sales expenses increased to 523,705,958.87 RMB in H1 2024, up from 457,912,599.45 RMB in H1 2023[178] - Interest income dropped to 3,960,073.02 RMB in H1 2024, down from 5,029,779.12 RMB in H1 2023[178] - Comprehensive income attributable to the parent company's shareholders reached 238,500,571.73 RMB in H1 2024, compared to 182,231,722.75 RMB in H1 2023[179] - Operating cash flow increased to 521,692,329.59 yuan in the first half of 2024, up from 360,360,814.25 yuan in the same period of 2023[182] - Sales revenue from goods and services reached 1,640,088,823.13 yuan in the first half of 2024, compared to 1,286,443,980.67 yuan in the first half of 2023[182] - Cash paid for employee compensation rose to 347,030,368.76 yuan in the first half of 2024, up from 306,676,511.05 yuan in the same period of 2023[182] - Investment activities resulted in a net cash outflow of 640,723,910.77 yuan in the first half of 2024, compared to 888,852,082.18 yuan in the first half of 2023[183] - Cash received from borrowing decreased to 408,600,000.00 yuan in the first half of 2024, down from 1,538,000,000.00 yuan in the first half of 2023[183] - Net cash outflow from financing activities was 167,076,906.49 yuan in the first half of 2024, compared to a net inflow of 453,618,365.64 yuan in the same period of 2023[183] - Parent company's operating cash flow increased to 541,299,942.01 yuan in the first half of 2024, up from 379,984,196.92 yuan in the first half of 2023[184] - Parent company's cash paid for employee compensation rose to 327,861,016.29 yuan in the first half of 2024, compared to 293,191,692.31 yuan in the same period of 2023[184] - Parent company's net cash outflow from investment activities was 109,666,017.06 yuan in the first half of 2024, compared to 1,197,204,211.41 yuan in the first half of 2023[185] - Parent company's net cash outflow from financing activities was 627,314,531.00 yuan in the first half of 2024, compared to a net inflow of 777,863,108.06 yuan in the same period of 2023[185] - Comprehensive income for the period reached 238,500,571.73 yuan, with a net profit attributable to parent company owners of 223,947,809.09 yuan[187] - Total owner's equity at the end of the period amounted to 5,564,137,210.03 yuan, up from 5,351,473,658.80 yuan at the beginning of the period[187][188] - Minority interest decreased by 7,934,691.81 yuan to 92,461,885.09 yuan[187][188] - Retained earnings increased by 152,805,208.64 yuan to 2,446,026,001.91 yuan[187][188] - Total comprehensive income for the previous year's same period was 182,231,722.75 yuan, with net profit attributable to parent company owners of 148,306,337.19 yuan[190] - Owner's equity at the end of the previous year's same period was 5,156,331,922.12 yuan, with minority interest of 101,099,666.52 yuan[190] - Capital reserve increased by 53,240,271.76 yuan during the current period, primarily due to share-based payments of 53,289,209.89 yuan[187] - Profit distribution to owners (or shareholders) amounted to 71,142,600.45 yuan[187] - Other comprehensive income for the current period was 14,552,762.64 yuan[187] - Comprehensive income for the period reached 284,714,798.18 yuan, driven by a net profit increase of 284,494,298.18 yuan[192] - Total owner's equity at the end of the period stood at 6,436,319,822.22 yuan, up from 6,169,507,352.73 yuan at the beginning of the period[192][193] - Profit distribution to owners (or shareholders) amounted to -71,142,600.45 yuan, indicating a significant payout[192] - The company's total equity increased by 266,812,469.49 yuan during the period, primarily due to comprehensive income and capital injections[192] - In the previous year, the company's total equity was 5,621,873,001.86 yuan, showing a year-over-year growth[194] Product Performance and Market Penetration - The company's flagship product, Camena (Icotinib Hydrochloride Tablets), generated sales of RMB 1.2 billion, accounting for 48% of total revenue[1] - The company's core product, Icotinib Hydrochloride Tablets (Conmana®), continues to maintain stable sales[17] - Enzotinib Capsules (Bemena®) and Bevacizumab Injection (MIL60, Beiantin®) showed significant revenue growth[17] - The company has five marketed drugs, with two recently included in the national medical insurance, accelerating market penetration[17] - Key products like Kaimeina, Beimeina, and Saimeina showed significant market growth, contributing to revenue[39] - The company achieved a 100% product qualification rate in the first half of 2024[37] - The company has successfully commercialized China's first self-developed small molecule lung cancer targeted drug, Kaimeina, and other innovative drugs[47] - The company's drug BPI-16350 (Tabecciclib Tartrate Capsules) has received NMPA acceptance for registration[47] - The company's drug Enzastaurin Capsules has received FDA acceptance for the treatment of ALK-positive NSCLC[47] - The company's drug Enzastaurin Capsules has a compound patent protection period until 2031-2037[49] - BPI-16350, a CDK4/6 inhibitor, has reached the NDA stage and is expected to contribute to future revenue growth[50] - Bemnara's first-line indication for ALK-positive NSCLC has been accepted by the US FDA, potentially becoming the first globally marketed lung cancer targeted innovative drug led by a Chinese pharmaceutical company[21] - Bemnara's Phase II-IIIB clinical trial for postoperative adjuvant treatment of ALK-positive NSCLC has completed patient enrollment[21] - Bemnara has published 69 articles with a total impact factor of 405.33, demonstrating its efficacy and safety in multiple studies[21] - In the eXalt 3 study, Bemnara showed a median PFS of 47.1 months in baseline brain metastasis-free patients and 23.9 months in baseline brain metastasis patients[21] - Bemnara's second-line clinical study updated results show a median OS of 42.8 months in patients with crizotinib-resistant NSCLC[21] - Bemnara's first-line and second-line indications have been included in the national medical insurance, significantly improving product accessibility[22] - Betta's Phase III clinical study for Bemnara showed a 12-week ORR of 48.6% vs 43.1% in the control group, proving bioequivalence[23] - Betta has acquired full sales royalties for Bemnara for 25 million RMB[23] - Bemnara's five major indications have been approved by the NMPA, making it a cornerstone drug in combination therapy[23] - MCLA-129 clinical trial for EGFR-mutated NSCLC patients approved by NMPA, with exclusive rights for BPI-D0316 in mainland China, Hong Kong, and Taiwan secured through a partnership with InventisBio in December 2018[25] - IBIOS-103 study published in The Lancet Respiratory Medicine shows median PFS of 22.1 months for Befotertinib vs. 13.8 months for Icotinib in EGFR-mutated NSCLC patients, with consistent benefits in patients with or without brain metastases[25] - Befotertinib (Saimena) included in 2024 CSCO guidelines as a Grade I recommendation for first-line treatment of EGFR-mutated NSCLC and for T790M-positive patients after first/second-generation TKI failure[25] - Fumetinib (Vometinib) approved for advanced RCC in June 2023, with median PFS of 10.0 months in combination with Everolimus vs. 6.4 months for Everolimus alone, and ORR of 24.8% vs. 8.3%[26] - EYP-1901, a sustained-release formulation of Vorolanib for ophthalmic indications, shows 65% and 64% of patients in 2mg and 3mg dose groups, respectively, requiring no anti-VEGF rescue therapy for 6 months in DAVIO 2 trial[26] - EYP-1901 achieves 12-month results in DAVIO 2 trial, with approximately half of patients requiring no anti-VEGF rescue therapy after a single injection, demonstrating good disease control[27] - Saimena strengthens the company's EGFR pathway product pipeline, with rapid market expansion post-NRDL inclusion, offering new treatment options for patients[25] - Fumetinib expands the company's oncology portfolio, with improved accessibility post-NRDL inclusion, and shows promising clinical and commercial potential in ophthalmic indications[27] - The company has published 6 SCI papers on Saimena with a total impact factor of 83.96, and 19 SCI papers on Fumetinib with a total impact factor of 81.26, presented at major international conferences[25][26] - The company focuses on unmet clinical needs, leveraging its R&D centers in Beijing and Hangzhou, and has built a product matrix with five marketed drugs, seeking breakthroughs in new targets and therapies[29] - BPI-16350, a CDK4/6 inhibitor, received NMPA acceptance for its marketing application in May 2024[34] - BPI-520105 and BPI-221351, targeting EGFR and IDH1/IDH2 mutations, had their clinical trial applications approved in March 2024[34] - EYP-1901, a treatment for wet AMD, received clinical trial approval in July 2024[34] - The company has 5 approved drugs, with 4 included in the National Reimbursement Drug List[38] - Strategic investments, such as in Wuhan Heyuan Biotechnology, are progressing with Phase III clinical studies completed[36] - The company is advancing multiple projects in NSCLC treatment, including postoperative adjuvant therapies for EGFR-mutated NSCLC[53] - Academic brand activities, such as the "Beda Speaker" and "Success Innovation Pharma Experience Sharing Conference," reinforce the company's market differentiation[54] - The company is exploring diverse cancer treatments, including targeted therapies, immunotherapies, and combination therapies, to provide new options for cancer patients[53] R&D and Innovation - R&D expenditure for the first half of 2024 amounted to RMB 600 million, representing 24% of total revenue[1] - The company plans to launch two new drugs, BPI-D0316 and CM082, in the second half of 2024, targeting NSCLC and RCC markets respectively[5] - The company's pipeline includes 15 innovative drugs in various stages of clinical trials, with 3 in Phase III[5] - International expansion efforts are underway, with plans to submit regulatory filings for Ensartinib in the US and EU by the end of 2024[5] - The company has initiated a strategic partnership with a leading global pharmaceutical company to co-develop and commercialize a novel oncology drug[5] - R&D investment in the first half of 2024 amounted to 381.85 million yuan, driving pipeline growth[33] - The company's R&D investment accounted for 38.32%, 41.12%, and 40.80% of its revenue over the past three years, supporting a robust pipeline of innovative drugs[52] - Balstilimab and Zalifrelimab, both monoclonal antibodies, are in Phase II trials for cervical cancer treatment, expanding the company's R&D pipeline[50] - MCLA-129, an EGFR/c-Met bispecific antibody, is in Phase I trials for treating EGFR-mutated advanced NSCLC, further diversifying the pipeline[50] - BPI-21668, a PI3Kα selective inhibitor, is in Phase I trials for advanced solid tumors, enhancing the company's oncology portfolio[51] - The company has successfully transitioned from a single product (Kaimeina) to five marketed products, demonstrating strong drug development capabilities[52] - BPI-16350's Phase III drug registration application has been accepted by the NMPA, highlighting the company's continuous innovation efforts[52] - The company is closely tracking industry innovation technologies, exploring new drugs and indications, and enhancing its R&D pipeline to manage new drug R&D and market risks[77] - The company has established strategic partnerships with companies like TianGuangShi, Yifang Biologics, EYPT, and C4T, leading to the approval of new drugs such as Beianting, Saimena, and Fumeina[55] - The company's investment in C4 Therapeutics, Inc. increased by 2.02% to 1,190,654,307.59 yuan, accounting for 13.02% of total assets[59] - The company's overseas assets, including Xcovery Holdings, Inc. and C4 Therapeutics, Inc., account for 26.21% and 3.29% of the company's net assets, respectively[60][61] - The company's construction-in-progress increased by 1.51% to 2,174,352,080.65 yuan due to increased investment in projects like the DreamWorks Phase II project and the Shengzhou Innovative Drug Industrialization Base project[59] - The company's investment in C4 Therapeutics, Inc. amounted to RMB 177,492,476.71, representing an 8.09% stake, with a profit of RMB 5,836,096.12 during the reporting period[65] - The total investment in the Menggongchang Phase II project reached RMB 1,419,098,225.96, with a progress rate of 78.84%[66] - The total investment in the Shengzhou Innovative Drug Industrialization Base project was RMB 730,235,762.78, with a progress rate of 74.51%[66] - The company's financial assets measured at

证券代码：300558 证券简称：贝达药业 公告编号：2024-054 贝达药业股份有限公司 第四届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长丁列明先生召集，会议通知于 2024 年 7 月 25 日以电 话、邮件等形式送达全体董事，董事会会议通知中包括会议的相关材料，同时列 明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2024 年 8 月 5 日在公司杭州总部行政大楼十五楼会议室召 开，采取现场会议和电话会议结合的方式现场投票表决。 3、本次董事会应到 11 人，实际出席会议人数 11 人。 4、本次董事会由董事长丁列明先生主持，公司董事会秘书吴灵犀先生列席 了本次会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《贝达药业股份有限公司章程》的有关规定。 二、董事会会议审议情况 于《证券时报》。《贝达药业股份有限公司 2024 年半年度报告》（公告编号： 2024-057）全文同日披露在巨潮资讯网。 表决结果：同意 11 票，反对 ...

证券代码：300558 证券简称：贝达药业 公告编号：2024-055 贝达药业股份有限公司 第四届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席张洋南先生召集，会议通知于 2024 年 7 月 25 日 以电子邮件、电话等形式送达全体监事，监事会会议通知中包括会议的相关材料， 同时列明了会议的召开时间、地点、内容和方式。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《贝达药业股份有限公司章程》的有关规定。 二、监事会会议审议情况 1、会议审议并通过了《2024 年半年度报告全文及摘要》 经审核，监事会认为董事会编制和审议公司《2024 年半年度报告全文及摘要》 的程序符合法律、行政法规及中国证券监督管理委员会、深圳证券交易所的规定， 报告内容真实、准确、完整地反映了公司 2024 年半年度的实际经营管理情况，不 存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同意 3 票，反对 0 票，弃权 0 票，议案获得通过。 《贝达药业股份有限公司 2 ...